Core Viewpoint - The Camping World Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company made misleading statements regarding its inventory management and financial performance during the specified class period [1][3]. Group 1: Allegations and Financial Performance - The lawsuit alleges that Camping World overstated its inventory management capabilities and retail demand, which led to the need for corrective inventory management that negatively impacted gross profit and margins [3]. - On October 28, 2025, Camping World reported a new vehicle revenue of $766.8 million for Q3 2025, a decrease of $58.1 million, or 7.0%, with an average selling price decrease of 8.6% and a gross margin decline of 12.7%, resulting in a nearly 25% drop in share price [4]. - On February 24, 2026, Camping World announced strict inventory management objectives and the suspension of its quarterly cash dividend, leading to a more than 16% decline in share price [5]. Group 2: Legal Process and Representation - Investors who purchased Camping World securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [6]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in the past five years [7]. - The firm has a history of significant recoveries, including the largest securities class action recovery in history at $7.2 billion in the Enron case [8].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for alleged violations of federal securities laws during the class period from May 20, 2024, to January 9, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Atara securities during the specified class period [2]. - The complaint alleges that defendants made false or misleading statements regarding manufacturing issues and regulatory prospects related to the tabelecleucel BLA [3]. - Specific allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval unlikely, overstated regulatory prospects, increased risk of regulatory scrutiny, and negatively impacted Atara's business and financial condition [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by May 22, 2026, although participation in any recovery does not require serving as lead plaintiff [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Via Transportation, Inc. for potential violations of federal securities laws following a significant drop in its stock price since its IPO in September 2025 [1][2]. Company Overview - Via Transportation went public on the NYSE in September 2025 at a price of $46 per share, claiming to develop software for on-demand and shared transit systems [3]. - The company has faced allegations that its business model is misrepresented, being described as a transit services contractor rather than a software platform [3]. Stock Performance - Following a report by Bleeker Street Research on March 10, 2026, Via Transportation's stock price fell by $0.49, or 2.6%, closing at $18.51 per share [3]. - Since its IPO, the stock has experienced a decline of over 70%, reaching a low of $13.11 per share [3]. Allegations and Investigation - The report claims that Via Transportation inflates its Annual Recurring Revenue (ARR) by booking large implementation fees and upfront software charges [3]. - Scott+Scott is alerting investors who may have suffered losses to discuss the investigation and potential recovery options [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Alight, Inc. for alleged misrepresentations regarding the company's growth potential and financial stability during a specified period [4]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased or acquired Alight common stock between November 12, 2024, and February 18, 2026 [1]. - Defendants are accused of making false statements about Alight's growth potential and financial stability [4]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file papers by May 15, 2026, and can still participate in any recovery without being the lead plaintiff [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - A securities class action lawsuit has been filed against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the drug AMT-130, which is being developed for Huntington's Disease [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the drug AMT-130 [4]. - Investors who acquired uniQure ordinary shares during the specified period are eligible to join the class action [1][2]. - The deadline to file as a lead plaintiff is April 13, 2026, and participation does not require serving as a lead plaintiff [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [3]. - The firm has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5].

Core Viewpoint - The Gartner class action lawsuit alleges that Gartner, Inc. and its executives made misleading statements regarding the company's contract value growth and consulting segment revenue, leading to significant stock price declines following disappointing earnings announcements [1][4][5][6]. Group 1: Lawsuit Details - The lawsuit, titled Schmidt v. Gartner, Inc., seeks to represent purchasers of Gartner common stock and claims violations of the Securities Exchange Act of 1934 [1]. - The class action alleges that Gartner misrepresented its contract value growth potential and downplayed risks associated with macroeconomic factors [4]. - Specific allegations include misleading statements about the improvement in the business environment for tariff-impacted companies and the subsequent impact on Gartner's growth [4]. Group 2: Financial Impact - On August 5, 2025, Gartner reported a decline in overall contract value growth from 7% to 5% and a drop in ex-federal contract value growth from 8% to 6%, resulting in a stock price drop of over 27% [5]. - On February 3, 2026, Gartner announced a further decline in contract value growth by an additional 2%, leading to a nearly 21% drop in stock price [6]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Gartner common stock during the class period to seek appointment as lead plaintiff [7]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [7]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [8]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [8].

<!doctype html> <!-- For structured data --> <!-- For language declaration --> Grocery Outlet Holding Corp. Class Action Lawsuit: Investors Face May 15, 2026, Deadline <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationDid you buy GO securities between August 5, 2025, and March 4, 2026?Affected GO Investor SummaryWho: Grocery Outlet Holding Corp. (NASDAQ: GO)What: Securities fraud class action lawsuit filedClass Period: August 5, 2025 through March 4, 2026Deadline to Seek Lead Pl ...

Core Viewpoint - The article discusses a class action lawsuit against monday.com Ltd. alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the company's financial outlook and growth projections [1][4]. Company Overview - monday.com Ltd. develops software applications and is publicly traded on NASDAQ under the ticker MNDY [3]. Allegations - The lawsuit claims that monday.com and its executives misled investors by creating a false impression of reliable revenue projections and growth, despite signs of decelerating customer growth and longer sales cycles [4]. - Specific allegations include that the company failed to disclose a slowdown in new customer growth and weaker expansion within existing accounts, making its $1.8 billion revenue target for 2027 increasingly unlikely to be met [4]. Stock Impact - Following the announcement on February 9, 2026, that the company would no longer discuss its 2027 targets, monday.com's stock price fell nearly 21% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased monday.com stock during the class period to seek appointment as lead plaintiff in the lawsuit [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - Ademi LLP is investigating Olaplex Holdings Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Henkel, which may not provide a fair price for public shareholders [1][3]. Group 1: Transaction Details - Olaplex shareholders are set to receive $2.06 per share in a cash transaction valued at approximately $1.4 billion [2]. - The transaction agreement includes provisions that significantly limit competing offers for Olaplex, imposing penalties if a competing bid is accepted [3]. Group 2: Investigation Focus - The investigation by Ademi LLP centers on the conduct of the Olaplex board of directors and whether they are fulfilling their fiduciary duties to all shareholders [3].

Core Viewpoint - A class action lawsuit has been filed against Apollo Global Management, Inc. regarding allegations of securities fraud and unlawful business practices related to the company's dealings with Jeffrey Epstein [2]. Group 1: Lawsuit Details - Investors who suffered losses in Apollo securities are encouraged to contact Pomerantz LLP to join the class action lawsuit, with a deadline to apply as Lead Plaintiff by May 1, 2026 [2]. - The lawsuit stems from reports indicating that Apollo executives, including CEO Marc Rowan, had discussions about tax arrangements with Epstein, contradicting previous statements that the firm had no business dealings with him [2]. Group 2: Stock Price Impact - Following the news of the lawsuit and allegations, Apollo's stock price dropped by $7.69, or 5.72%, closing at $126.85 per share on February 3, 2026 [3]. - A subsequent report led to another decline in Apollo's stock price by $5.99, or 5%, closing at $113.73 per share on February 23, 2026 [5]. Group 3: Regulatory Concerns - The American Federation of Teachers and the American Association of University Professors have urged the SEC to investigate Apollo's communications with investors, claiming they misrepresented the firm's connections to Epstein [4]. - Experts have described Apollo's responses to these allegations as inadequate, raising questions about the transparency of the company's disclosures [4].